RBC Trims Price Target on Bio-Rad Laboratories to $402 From $414, Keeps Outperform Rating
Bio-Rad Laboratories (BIO) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $300 to $430.
Express News | Bio Rad Laboratories Inc : RBC Cuts Target Price to $402 From $414
Top Gap Ups and Downs on Monday: AVGO, DELL, SONY and More
Gaps can show signals that something important has happened to the fundamental or the psychology of traders that accompanies this market movement.
Bio-Rad Laboratories on Pace for Largest Percent Increase Since December 2023 -- Data Talk
Bio-Rad Laboratories, Inc. Class A (BIO) is currently at $298.34, up $16.08 or 5.7% --Would be highest close since May 15, 2024, when it closed at $300.97 --On pace for largest percent increase sinc
$842.7 Million SDS Poly Acrylamide Gel Electrophoresis Market Forecast, 2030 - Featuring Profiles of 13 Companies Including Abcam, Bio-Rad Laboratories, GE Healthcare, and Thermo Fisher Scientific
There's Reason For Concern Over Bio-Rad Laboratories, Inc.'s (NYSE:BIO) Price
With a median price-to-sales (or "P/S") ratio of close to 3.1x in the Life Sciences industry in the United States, you could be forgiven for feeling indifferent about Bio-Rad Laboratories, Inc.'s (NY
Bio-Rad Laboratories(BIO.US) Officer Sells US$104.02K in Common Stock
$Bio-Rad Laboratories(BIO.US)$ Officer Crowley Michael sold 369 shares of common stock on Jun 13, 2024 at an average price of $281.9064 for a total value of $104.02K.Source: Announcement What is state
Is Bio-Rad Laboratories (BIO) a Lucrative Investment?
Form 144 | Bio-Rad Laboratories(BIO.US) Officer Proposes to Sell 104.02K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 13, $Bio-Rad Laboratories(BIO.US)$ Officer Crowley Michael intends to sell 369 shares of its common stock on Jun 13, with a total market value of approximately $104.02K.
Citi Maintains Bio-Rad Laboratories(BIO.US) With Hold Rating, Cuts Target Price to $300
Citi analyst Patrick B Donnelly maintains $Bio-Rad Laboratories(BIO.US)$ with a hold rating, and adjusts the target price from $365 to $300.According to TipRanks data, the analyst has a success rate o
Bio-Rad Laboratories Coverage Assumed by Jefferies at Hold Vs Previous Rating of Buy
Bio-Rad Laboratories Coverage Assumed by Jefferies at Hold Vs Previous Rating of Buy
Express News | Jefferies Assumes Bio-Rad Laboratories at Hold, Lowers Price Target of $315
Express News | Bio Rad Laboratories Inc : Jefferies Assumes Coverage With Hold Vs Buy Rating; Price Target $315 Vs $440
Express News | Bio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics Group
Bio-Rad's Management to Participate in Fireside Chat During Jefferies Global Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE:BIO), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K.
Express News | Federal Register Reported FDA Announcing Revocation Of EUAs Issued To Bio-Rad Laboratories For The Bio-Rad Sars-Cov-2 DDPCR Kit
Express News | U.S. Federal Register: FDA Revoked Authorizations Under Federal Food, Drug, and Cosmetic Act as Requested by the Authorization Holders
Express News | U.S. Federal Register: FDA Announcing Revocation of Euas Issued to Fast Track Diagnostics Luxembourg S.á.r.l. for Ftd Sars-Cov-2
Express News | U.S. Federal Register: FDA Announcing Revocation of Euas Issued to Bio-Rad Laboratories for the Bio-Rad Sars-Cov-2 Ddpcr Kit
Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Reported, And Analysts Assigned A US$394 Price Target
Last week saw the newest quarterly earnings release from Bio-Rad Laboratories, Inc. (NYSE:BIO), an important milestone in the company's journey to build a stronger business. The analysts typi